|
業務類別
|
Biotechnology |
|
業務概覽
|
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
| 公司地址
| 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612 |
| 電話號碼
| +1 949 238-8090 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.eledon.com |
| 員工數量
| 31 |
| Dr. Steven N. Perrin, PhD |
President, Chief Scientific Officer, Director |
美元 455.26K |
29/04/2025 |
| Mr. Bryan E. Smith |
General Counsel, Corporate Secretary and Chief Compliance Officer |
-- |
29/04/2025 |
| Dr. David-Alexandre C. Gros, M.D. |
Director and Chief Executive Officer |
美元 582.27K |
29/04/2025 |
| Mr. Paul Sean Little |
Chief Financial Officer and Principal Accounting Officer |
美元 459.43K |
29/04/2025 |
|
|
| Mr. Keith A. Katkin |
Chairman of the Board |
29/04/2025 |
| Dr. Steven N. Perrin, PhD |
President, Chief Scientific Officer, Director |
29/04/2025 |
| Mr. James Robinson |
Independent Director |
29/04/2025 |
| Dr. Jan L. Hillson, M.D. |
Independent Director |
29/04/2025 |
| Dr. June Lee, M.D. |
Independent Director |
29/04/2025 |
| Dr. David-Alexandre C. Gros, M.D. |
Director and Chief Executive Officer |
29/04/2025 |
| Mr. John S. McBride |
Independent Director |
29/04/2025 |
| Dr. Allan Douglas Kirk, F.A.C.S.,M.D.,PhD |
Independent Director |
29/04/2025 |
|
|
|
|
